MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinsonism"

  • MDS Virtual Congress 2020

    Higher adherence to MIND diet associated with later onset of Parkinson’s disease

    A. Metcalfe-Roach, M. Cirstea, A. Yu, E. Golz, K. Sundvick, D. Kliger, B. Finlay, S. Appel-Cresswell (Vancouver, BC, Canada)

    Objective: This study evaluated the impact of MIND diet adherence on Parkinson’s disease (PD) onset and related symptoms. Background: PD is a common neurodegenerative disease…
  • MDS Virtual Congress 2020

    Sleep disturbances in Vascular Parkinsonism (VP) and Parkinson’s Disease (PD) patients in early stages

    R. Raimundo, M. Mendes, R. Jesus, C. Azoia, A. Marques, A. Almeida, A. Velon (Vila Real, Portugal)

    Objective: Compare sleep disturbances between VP and PD patients. Background: Sleep disorders in PD patients are well recognized, ranging from nocturnal symptoms such as insomnia,…
  • MDS Virtual Congress 2020

    A Parkinson’s disease (PD) case with underlying cerebral small vessel disease (CSVD)

    L.X Cao, W. Dong, Y. Li, G. Du, J.H Yin, Q. Yang, Y.Q Zhang, B. Chen, Y. Huang (Beijing, China)

    Objective: Emphasis of CSVD in PD through clinical-pathological correlation study. Background: PD affects 1.7%, while CSVD affects about 45% [1], of the population aged over…
  • MDS Virtual Congress 2020

    Increased risk of Parkinson’s disease in patients with schizophrenia spectrum disorders

    T. Kuusimäki, H. Al-Abdulrasul, S. Kurki, J. Hietala, S. Hartikainen, M. Koponen, A. Tolppanen, V. Kaasinen (Turku, Finland)

    Objective: To investigate the coincidence of Parkinson’s disease (PD) and schizophrenia spectrum disorders (SCD). Background: PD is characterized by a progressive loss of mesostriatal dopamine…
  • MDS Virtual Congress 2020

    In vivo imaging of presynaptic terminal loss in early Parkinson’s disease

    A. Delva, D. Van Weehaeghe, M. Koole, K. Van Laere, W. Vandenberghe (Leuven, Belgium)

    Objective: To determine the magnitude and anatomical extent of presynaptic terminal damage in early Parkinson’s disease (PD) in vivo, we performed a PET study with…
  • MDS Virtual Congress 2020

    Effect of home-based functional training program on enhancing gross and fine upper extremity function in people with Parkinson’s disease – a randomized controlled trial

    M.Y Mak, L.J Ren, I.K Wong-Yu (Hong Kong SAR, China)

    Objective: The present study aimed to examine the effect of functional training on enhancing the gross and fine upper limb extremity function in people with…
  • MDS Virtual Congress 2020

    Allogeneic bone marrow-derived mesenchymal stem cells safety and tolerability in idiopathic Parkinson’s disease

    M. Schiess, J. Suescun, M. Doursout, C. Adams, C. Green, J. Saltarrelli, S. Savitz, T. Ellmore (Houston, TX, USA)

    Objective: Prove safety and feasibility of delivering allogeneic bone marrow-derived mesenchymal stem cells (MSC) intravenously in escalated doses to patients with idiopathic Parkinson’s disease (PD).…
  • MDS Virtual Congress 2020

    Effect of Lactobacillus casei supplementation on clinical response, gut microbiota and faecal metabolites in patients with Parkinson’s disease: A randomized, double-blind, placebo-controlled trial

    X.D Yang, X.Q He, S.Q Xu, VV. Qian, Y. Zhang, YY. Song, Q. Xiao (Shanghai, China)

    Objective: To evaluate the effect of Lactobacillus casei strain Shirota (LcS) supplementation on symptoms, gut microbiota and faecal metabolites in patients with Parkinson's disease (PD).…
  • MDS Virtual Congress 2020

    Maintenance of safinamide 100 mg daily long-term

    N. FONCEA (Galdakao, Spain)

    Objective: Evaluating the maintenance of safinamide 100 mg daily as a long-term treatment Background: The effects of safinamide were investigated in studies 016, 018 and…
  • MDS Virtual Congress 2020

    Anticholinergic Burden in Parkinson’s Disease Patients in India – A Hospital Based Study

    A. Saini, R. Rajan, R. Anandapadmanabhan, V. Venogopalan, A. Gupta, B. Verma, N. Choudhary, R. Bhatia, M. Singh, A. Srivastava, P. Srivastava (New Delhi, India)

    Objective: To determine the cumulative anticholinergic burden in Indian Parkinson’s disease (PD) patients and to correlate the same with cognitive impairment and gait disturbance. Background:…
  • « Previous Page
  • 1
  • …
  • 100
  • 101
  • 102
  • 103
  • 104
  • …
  • 425
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley